VivoSeq
Neurology

Thoracic Outlet Syndrome

4

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Thoracic Outlet Syndrome is an early-stage landscape with 4 programs across 3 companies. The most active players are Revance Therapeutics, Inc., Vitae Pharmaceuticals Inc., an Allergan affiliate, Fresenius Kabi Oncology Ltd.. 2 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

6/100

Mech. Concentration

33/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

R

Revance Therapeutics, Inc.

1 program

Phase 1V

Vitae Pharmaceuticals Inc., an Allergan affiliate

1 program

Phase 2F

Fresenius Kabi Oncology Ltd.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

5

clinical trials

Unknown status2 · 40%
Completed1 · 20%
Enrolling by invitation1 · 20%
Not yet recruiting1 · 20%

Clinical Trials

Trial Activity

Botulinum Toxin Injections for Thoracic Outlet Syndrome
Unknown status·UUniversity of British Columbia·Phase 1·NCT01405482·60 enrolled
Treatment of Thoracic Outlet Syndrome (TOS) With Botox
Completed·UUniversity of British Columbia·Phase 2·NCT00444886·40 enrolled
A Study of Paravertebral Block in Thoracic Outlet Syndrome
Enrolling by invitation·MMayo Clinic·Phase 4·NCT05544721·50 enrolled
Whiplash-induced Thoracic Outlet Syndrome Treated With Botulinum Toxin.
Unknown status·KKing, David, MD·Phase 4·NCT05536570·15 enrolled
The Effect of Motivational Interviewing on Thoracic Outlet Syndrome Symptoms in Patients With Thoracic Outlet Syndrome
Not yet recruiting·HHacettepe University·Preclinical·NCT07668206·70 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)